Get the latest tech news
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease
After transplantation into the brain of patients with Parkinson’s disease, allogeneic dopaminergic progenitors derived from induced pluripotent stem cells survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.
Moreover, no patients displayed T2-weighted and fluid-attenuated inversion recovery (FLAIR) hyperintense regions nor appreciable uptake of the translocator protein-ligand, fluorine-18-flutriciclamide ( 18 F-GE180: a marker of microglial activation) 17, indicative of apparent inflammation in the putamen and surrounding areas. This lack of correlation may be due to the complexity of cell replacement therapy: 18 F-DOPA uptake does not necessarily reflect the activation of postsynaptic neurons, and motor symptoms are influenced by both dopaminergic and non-dopaminergic neural circuits. Immunostaining was performed after incubation with an antigen retrieval reagent (LSI Medience) and blocking with 0.3% Triton X-100 and 2% donkey serum for 1 h. Fluorescence images were obtained by using confocal laser microscopes (Fluoview FV1200, Olympus).
Or read this on Hacker News